Search clinical trials for: High Risk of cardiovascular events

Total 440841 results

Eli Lilly and Company

Not yet recruiting

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)

Overweight and Obesity

United States, Canada, Australia, Germany, Mexico, Argentina, Brazil, Hungary, Austria, India, Poland, Slovakia, Spain, Netherlands, Turkey, Czechia, United Kingdom, Denmark, Puerto Rico, France, Israel
Beijing Tiantan Hospital

Not yet recruiting

Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4）

TIA | Ischemic Stroke, Acute | Symptomatic Intracranial Artery Stenosis

China
University of Bonn
Federal Ministry of Food and Agriculture (BMEL); Federal Office for Agriculture...

Recruiting

Acute Effects of Legume-enriched Meals Compared to Western Diet Meals on Postprandial Metabolism in Participants With Increased Cardiometabolic Risk (LeguPlan_1)

Cardiovascular Diseases | Metabolic Syndrome

Germany
Novartis Pharmaceuticals

Recruiting

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Primary Prevention of Atherosclerotic Cardiovascular Disease

United States, China, Italy, Spain, France, Netherlands, Poland, Switzerland, Taiwan, Greece, Thailand, Brazil, India, Hungary, Latvia, Mexico, Israel, Malaysia, Turkey, Argentina, Singapore, Australia, Belgium, Bulgaria, Denmark, Croatia, South... and more
Novartis Pharmaceuticals

Recruiting

Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera (Prospero)

Polycythemia Vera

Italy
Yonsei University
Severance Hospital; Genoss Co., Ltd.

Recruiting

Genoss DES in Patients With a High Risk of Ischemic Events (GENTLE Registry)

Coronary Artery Disease | Drug-eluting Stent

Korea, Republic of
yuanli Zhao
Peking University International Hospital

Not yet recruiting

NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events (NICE-MMD)

Ischemic Stroke | Transient Ischemic Attack | Moyamoya Disease | Ischemic Cerebrovascular Accident | Ischemic Cerebral Infarction

China
Eli Lilly and Company

Completed

A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events (KRAKEN)

Lipoprotein Disorder

Australia, China, Hungary, Brazil, Japan, Germany, Netherlands, United States
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events (SANTORINI)

Cardiovascular Diseases | Dyslipidemia | Hypercholesterolemia | Atherosclerotic Cardiovascular Disease

Finland, Netherlands, Spain, Belgium, Sweden, Austria, United Kingdom, Switzerland, Denmark, France, Germany, Portugal, Italy, Ireland
Silence Therapeutics plc

Active, not recruiting

Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Cardiovascular Diseases | Atherosclerosis | Lipoprotein(a)

Australia, Czechia, Denmark, Netherlands, Slovakia, South Africa, United Kingdom
Esperion Therapeutics, Inc.
The Cleveland Clinic

Completed

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo (CLEAR Outcomes)

Cardiovascular Diseases | Statin Adverse Reaction

Belgium, Germany, United States, Austria, Estonia, Mexico, New Zealand, Spain, Russian Federation, Netherlands, Hungary, Australia, Denmark, South Africa, United Kingdom, Bulgaria, Argentina, Romania, Turkey, Croatia, Serbia, Canada, Lithuan... and more
Yonsei University

Active, not recruiting

A Randomized Comparison of CLOpidogrel Monotherapy Versus Extended Dual-antiplatelet Therapy Beyond 12 Months After Implantation of Drug-eluting StEnts in High-risk Lesions or Patients; A-CLOSE Trial

Coronary Artery Disease | DES

Korea, Republic of
Novartis

Terminated

Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH)

Hypertension

United States, Denmark, Finland, Norway, Sweden
Sanofi

Active, not recruiting

Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin

Venous Thromboembolism

United States
Amarin Pharma Inc.

Completed

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin (REDUCE-IT)

Cardiovascular Diseases

United States, Australia, Canada, India, Netherlands, New Zealand, Poland, Romania, Russian Federation, South Africa, Ukraine
Centre Hospitalier Universitaire de Saint Etienne

Terminated

Stress Test on the Prediction of Cardiovascular Events in a High-risk Firefighter Population (FIRE-PREV)

Firefighter | High Cardiovascular Risk

France
Beijing Tiantan Hospital
Ministry of Science and Technology of the People´s Republic of China

Completed

Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II (CHANCE-2)

Stroke | Transient Ischemic Attack

China
Resverlogix Corp
PPD; ICON plc; Medidata Solutions

Completed

Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD (BETonMACE)

Coronary Artery Disease | Diabetes Mellitus, Type 2

Netherlands, Taiwan, Argentina, Israel, Poland, Russian Federation, Australia, Belgium, Serbia, Bulgaria, Hungary, Slovakia, Mexico, Croatia, Germany
Quark Pharmaceuticals

Terminated

QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

Cardiac Surgery

United States, Germany, Spain, Australia, Austria, Canada, New Zealand, United Kingdom, Belgium, Czechia, France
Assistance Publique - Hôpitaux de Paris

Unknown

Evaluation of NETs in Patients With Solid Cancers Associated With a High Risk of Venous Thromboembolic Events (Flownet)

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer

France
Beijing Tiantan Hospital
University of California, San Francisco

Completed

Clopidogrel in High-risk Patients With Acute Non-disabling Cerebrovascular Events (CHANCE)

Stroke | Transient Ischemic Attack

China
Miodrag Filipovic, Prof. Dr. med.

Completed

Biomarkers, Blood Pressure, BIS: Risk Stratification/Management of Patients at Cardiac Risk in Major Noncardiac Surgery (BBB)

Heart Failure | Stroke | Postoperative Complications | Renal Insufficiency, Chronic | Death | Acute Coronary Syndrome | Acute Kidney Injury | Hypotension | Coronary Occlusion

Switzerland
Montreal Heart Institute
Canadian Institutes of Health Research (CIHR)

Completed

Non-isotope Based Imaging Modalities vs Technetium-99m Single-Photon Emission Computed Tomography(99mTcSPECT) (MITNECB5)

Myocardial Ischemia

Canada
AstraZeneca
Bristol-Myers Squibb; Hadassah Medical Organization; The TIMI Study Group

Completed

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58)

Diabetes Mellitus, Non-Insulin-Dependent | High Risk for Cardiovascular Event

United States, Canada, France, Italy, Netherlands, Spain, Belgium, Thailand, Vietnam, Bulgaria, Korea, Republic of, Brazil, Philippines, Russian Federation, Turkey, Taiwan, Australia, Israel, South Africa, Germany, Japan, Czechia, H... and more
Novo Nordisk A/S

Completed

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, India, Italy, Mexico, Russian Federation, United Kingdom, Spain, Malaysia, Croatia, Greece, Korea, Republic of, Japan, South Africa, Algeria, Thailand, Argentina, Brazil, Canada, Romania
Eisai Inc.
Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization

Completed

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors (CAMELLIA-TIMI)

Obesity | Cardiovascular Disease | Overweight | Type 2 Diabetes | High Cardiovascular Risk

United States, Canada, Poland, Australia, Mexico, New Zealand, Bahamas, Chile
Pfizer

Terminated

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2)

Cardiovascular Disease

United States, Finland, Netherlands, Spain, Belgium, Germany, Czechia, Switzerland, Denmark, Australia, United Kingdom, Korea, Republic of, Hungary, Israel, Poland, Taiwan, Mexico, Turkey, Ireland, Canada, New Zealand, South Africa, Brazi... and more
Amgen

Completed

A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects (AMG145)

Hypercholesterolemia and High Risk for Cardiovascular Events

Japan
Pfizer

Completed

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events (SPIRE-LDL)

Hyperlipidemia

United States, Spain, Taiwan, United Kingdom, Canada, Mexico, France, Hungary, Lithuania, Colombia, Romania, Russian Federation
Pfizer

Completed

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events (SPIRE-LL)

Hyperlipidemia

Finland, Netherlands, United States, Canada, Sweden, Korea, Republic of, Singapore, Czechia, Poland, United Kingdom, Puerto Rico, Norway
Pfizer

Terminated

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1)

Cardiovascular Disease

Finland, United States, Netherlands, Spain, Korea, Republic of, China, Israel, Belgium, Germany, Australia, Czechia, Taiwan, Denmark, United Kingdom, Hungary, Poland, France, Mexico, Turkey, Canada, New Zealand, Colombia, Switzerland, Irelan... and more
Pfizer

Completed

A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia (SPIRE-FH)

Heterozygous Familial Hypercholesterolemia

Canada, Netherlands, United Kingdom, United States, Spain, Poland, Finland, Norway, South Africa, Italy, Bulgaria
Pfizer

Completed

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events (SPIRE-HR)

Hyperlipidemia

Korea, Republic of, United States, Australia, Germany, Poland, Canada, Italy, Hong Kong, Czech Republic
Seoul St. Mary's Hospital
AstraZeneca; The Catholic University of Korea; Chonnam National University

Unknown

CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Acute Myocardial Infarction II (COREA-AMI II)

Bleeding | Percutaneous Coronary Intervention | Acute Myocardial Infarction | Major Adverse Cardiovascular Events

Korea, Republic of
Asan Medical Center
Korea Otsuka Pharmaceutical Co., Ltd.

Unknown

PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage (PICASSO)

Brain Ischemia | Intracranial Hemorrhages

Korea, Republic of, Philippines, China
Amgen

Completed

Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk (AMG145)

Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events

Japan
Kyoto Prefectural University of Medicine

Terminated

Effects of Telmisartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients (KCPS)

Myocardial Ischemia | Hypertension | Angina Pectoris | Acute Coronary Syndrome | Acute Myocardial Infarction

Japan
Kiyuk Chang
The Catholic University of Korea; Chonnam National University

Completed

CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Acute Myocardial Infarction (COREA-AMI)

Myocardial Infarction | Percutaneous Coronary Intervention | Long-term Major Cardiovascular Events
Technical University of Munich

Completed

Correlation Between Reticulated Platelets and Major Adverse Cardiac and Cerebrovascular Events After Noncardiac Surgery

Stroke | Angina Pectoris | Deep Vein Thrombosis | Pulmonary Embolism | Congestive Heart Failure | Cardiac Death

Germany
AstraZeneca
Bristol-Myers Squibb

Completed

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications (SAVOR- TIMI 53)

Type 2 Diabetes Mellitus

Sweden, United States, Australia, Brazil, Czech Republic, Italy, Mexico, Peru, Poland, Russian Federation, South Africa, Spain, United Kingdom, Germany, China, Hungary, Netherlands, Canada, Hong Kong, Argentina, Chile, France, Israel, Puerto Rico and more
Boehringer Ingelheim

Completed

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

Cardiovascular Diseases

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Italy, Korea, Republic of, Malaysia, Mexico, Netherlands, New Zealand and more
The Japanese Society of Hypertension

Unknown

Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients

Cardiovascular Diseases | Hypertension

Japan
Children's Hospital of Fudan University

Not yet recruiting

High-Intensity Interval Training(HIIT) on Cardio-metabolic Risk in School-age Children

Cardiovascular Syndrome, Metabolic
Monash University Malaysia
Ministry of Higher Education, Malaysia

Recruiting

Peer-led Digital Health Lifestyle Intervention for a Low Income Community at Risk for Cardiovascular Diseases (MYCardio-PEER)

Primary Prevention of Cardiovascular Diseases

Malaysia
The First Affiliated Hospital of Soochow University

Not yet recruiting

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Multiple Myeloma | Newly Diagnosed | MRD | High Risk
Shanghai Changzheng Hospital
CARsgen Therapeutics Co., Ltd.

Not yet recruiting

Study of CT071 Injection in HRNDMM

High-risk Newly Diagnosed Multiple Myeloma (HRNDMM)
Beijing 302 Hospital
LanZhou University; Shengjing Hospital; Qianfoshan Hospital; The Affiliated Hospital... and other collaborators

Recruiting

Noninvasive Diagnosis Model for High-risk Varices in Cirrhosis (NID-HRV)

Liver Cirrhosis | Varices

China
Beijing Tsinghua Chang Gung Hospital

Recruiting

Construction of a Prediction Model for MACCE in Elderly Patients After Elective Non-cardiac Surgery

Postoperative Complications | Cerebrovascular Accident | Major Adverse Cardiac Events | Models

China
West Michigan Cancer Center
Veta Health

Recruiting

Expanding Access to Care Through Telemedical Support for Vital Sign Monitoring in High-risk Patients With Cancer

Hypertension

United States
Supergene, LLC

Not yet recruiting

Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism

Pulmonary Embolism

Russian Federation

Search clinical trials for: High Risk of cardiovascular events

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations